23 Feb 2006 - Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex, announced that its client Chugai Pharmaceutical Co., Ltd. completed their assessment of certain of its Clonetics(R) Conditionally Immortalized Cell Lines under the previously announced evaluation license and signed a one-year renewable license agreement to use a cell line in Chugai pharmaceutical drug discovery programs. Chugai is the first company to license this technology in Japan.
Under the terms of the renewable license agreement, Chugai Pharmaceutical Company will use one of the conditionally immortalized cell lines for a period of one year in their pharmaceutical drug discovery program. The license agreement has been lead by Cambrex's exclusive distributor in Japan, GeneFrontier Corporation. Further financial details of the agreement are not disclosed.
The licensed cell lines were created using a clone of a specially modified large T antigen and licensed telomerase technology. Cambrex continues to invest in several programs to conditionally immortalize different cell types critical to understand and manage metabolic disease.
 |
www.bionity.com/news/e/52509 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/52509 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |